The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.

Moderna will get $50 million upfront and up to $110 million in near-term development and regulatory milestone payments, among other financial terms.

The trial will include patients with pancreatic, colorectal, non-small cell lung, and other cancers that harbor KRAS G12V mutations.

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see ...

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...

The company's Phase I/II trial of the drug demonstrated a 46.5 percent overall response rate in patients with FGFR2 fusions or rearrangements.

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

The firm said it expects to advance development of cell therapies and radioconjugates for cancer, blood disorders, and autoimmune diseases in China.

The firm is raising funds through a reserved offering of new shares, which will fund development of two gene therapies for congenital hearing loss.

The company will use the funds to further commercialize its FDA-approved software for sepsis risk assessment, and to integrate precision sepsis diagnostics with personalized therapy.